Literature DB >> 25892360

Translational implication of Kallmann syndrome-1 gene expression in hepatocellular carcinoma.

Yuri Tanaka1, Mitsuro Kanda1, Hiroyuki Sugimoto1, Dai Shimizu1, Satoshi Sueoka1, Hideki Takami1, Kazuhiro Ezaka1, Ryoji Hashimoto1, Yukiyasu Okamura2, Naoki Iwata1, Chie Tanaka1, Suguru Yamada1, Tsutomu Fujii1, Goro Nakayama1, Masahiko Koike1, Shuji Nomoto3, Michitaka Fujiwara1, Yasuhiro Kodera1.   

Abstract

Accumulation of epigenetic alterations causes inactivation of tumor suppressors and contributes to the initiation and progression of hepatocellular carcinoma (HCC). Identification of methylated genes is necessary to improve our understanding of the pathogenesis of HCC and develop novel biomarkers and therapeutic targets. The Kallmann syndrome-1 (KAL1) gene encodes an extracellular matrix-related protein with diverse oncological functions. However, the function of KAL1 in HCC has not been examined. We investigated the methylation status of the KAL1 promoter region in HCC cell lines, and evaluated KAL1 mRNA levels and those of genes encoding potential interacting cell adhesion factors. KAL1 mRNA expression level was heterogeneous in nine HCC cell lines, and reactivation of KAL1 mRNA expression was observed in cells with promoter hypermethylation of KAL1 gene after demethylation. In addition, KAL1 mRNA levels inversely correlated with those of ezrin in all nine HCC cell lines. KAL1 expression levels in 144 pairs of surgically-resected tissues were determined and correlated to clinicopathological parameters. KAL1 mRNA level was independent of the background liver status, whereas HCC tissues showed significantly lower KAL1 mRNA levels than corresponding noncancerous liver tissues. Downregulation of KAL1 mRNA in HCC was significantly associated with malignant phenotype characteristics, including elevated tumor markers, larger tumor size, vascular invasion, and hypermethylation of KAL1. Patients with downregulation of KAL1 were more likely to have a shorter overall survival than other patients, and multivariate analysis identified downregulation of KAL1 as an independent prognostic factor (hazard ratio 2.04, 95% confidence interval 1.11-3.90, P=0.022). Our results indicated that KAL1 may act as a putative tumor suppressor in HCC and is inactivated by promoter hypermethylation. KAL1 may serve as a biomarker of malignant phenotype of HCC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25892360     DOI: 10.3892/ijo.2015.2965

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

Review 1.  Molecular mechanisms of peritoneal dissemination in gastric cancer.

Authors:  Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

2.  An integrative approach to assess X-chromosome inactivation using allele-specific expression with applications to epithelial ovarian cancer.

Authors:  Nicholas B Larson; Zachary C Fogarty; Melissa C Larson; Kimberly R Kalli; Kate Lawrenson; Simon Gayther; Brooke L Fridley; Ellen L Goode; Stacey J Winham
Journal:  Genet Epidemiol       Date:  2017-11-08       Impact factor: 2.135

3.  ANOS1: a unified nomenclature for Kallmann syndrome 1 gene (KAL1) and anosmin-1.

Authors:  Fernando de Castro; Ruth Seal; Roberto Maggi
Journal:  Brief Funct Genomics       Date:  2017-07-01       Impact factor: 4.241

4.  In Vitro Identification of New Transcriptomic and miRNomic Profiles Associated with Pulmonary Fibrosis Induced by High Doses Everolimus: Looking for New Pathogenetic Markers and Therapeutic Targets.

Authors:  Simona Granata; Gloria Santoro; Valentina Masola; Paola Tomei; Fabio Sallustio; Paola Pontrelli; Matteo Accetturo; Nadia Antonucci; Pierluigi Carratù; Antonio Lupo; Gianluigi Zaza
Journal:  Int J Mol Sci       Date:  2018-04-20       Impact factor: 5.923

5.  Network-based analysis of prostate cancer cell lines reveals novel marker gene candidates associated with radioresistance and patient relapse.

Authors:  Michael Seifert; Claudia Peitzsch; Ielizaveta Gorodetska; Caroline Börner; Barbara Klink; Anna Dubrovska
Journal:  PLoS Comput Biol       Date:  2019-11-04       Impact factor: 4.475

6.  A Comprehensive Transcriptomic Analysis of Arsenic-Induced Bladder Carcinogenesis.

Authors:  Vaibhav Shukla; Balaji Chandrasekaran; Ashish Tyagi; Ajit Kumar Navin; Uttara Saran; Rosalyn M Adam; Chendil Damodaran
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

7.  An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma.

Authors:  Mitsuro Kanda; Kenta Murotani; Hiroyuki Sugimoto; Takashi Miwa; Shinichi Umeda; Masaya Suenaga; Masamichi Hayashi; Norifumi Hattori; Chie Tanaka; Daisuke Kobayashi; Suguru Yamada; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Oncotarget       Date:  2017-08-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.